Full Text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

While human extracellular vesicles (EVs) have attracted a big deal of interest and have been extensively characterized over the last years, plant-derived EVs and nanovesicles have earned less attention and have remained poorly investigated. Although a series of investigations already revealed promising beneficial health effects and drug delivery properties, adequate (pre)clinical studies are rare. This fact might be caused by a lack of sources with appropriate qualities. Our study introduces plant cell suspension culture as a new and well controllable source for plant EVs. Plant cells, cultured in vitro, release EVs into the growth medium which could be harvested for pharmaceutical applications. In this investigation we characterized EVs and nanovesicles from distinct sources. Our findings regarding secondary metabolites indicate that these might not be packaged into EVs in an active manner but enriched in the membrane when lipophilic enough, since apparently lipophilic compounds were associated with nanovesicles while more hydrophilic structures were not consistently found. In addition, protein identification revealed a possible explanation for the mechanism of EV cell wall passage in plants, since cell wall hydrolases like 1,3-β-glucosidases, pectinesterases, polygalacturonases, β-galactosidases and β-xylosidase/α-L-arabinofuranosidase 2-like are present in plant EVs and nanovesicles which might facilitate cell wall transition. Further on, the identified proteins indicate that plant cells secrete EVs using similar mechanisms as animal cells to release exosomes and microvesicles.

Details

Title
Plant Extracellular Vesicles and Nanovesicles: Focus on Secondary Metabolites, Proteins and Lipids with Perspectives on Their Potential and Sources
Author
Woith, Eric 1   VIAFID ORCID Logo  ; Guerriero, Gea 2   VIAFID ORCID Logo  ; Hausman, Jean-Francois 2   VIAFID ORCID Logo  ; Renaut, Jenny 3   VIAFID ORCID Logo  ; Leclercq, Céline C 3   VIAFID ORCID Logo  ; Weise, Christoph 4   VIAFID ORCID Logo  ; Legay, Sylvain 2 ; Weng, Alexander 1   VIAFID ORCID Logo  ; Melzig, Matthias F 1 

 Freie Universität Berlin, Institute of Pharmacy, Pharmaceutical Biology, Dahlem Center of Plant Sciences, Königin-Luise-Str. 2+4, D-14195 Berlin, Germany; [email protected] (E.W.); [email protected] (M.F.M.) 
 Luxembourg Institute of Science and Technology, Environmental Research and Innovation Department, 5 rue Bommel, L-4940 Hautcharage, Luxembourg; [email protected] (J.-F.H.); [email protected] (S.L.) 
 Luxembourg Institute of Science and Technology, Environmental Research and Innovation Department, 41 Rue du Brill, L-4422 Belvaux, Luxembourg; [email protected] (J.R.); [email protected] (C.C.L.) 
 Freie Universität Berlin, Institute of Chemistry and Biochemistry, Core Facility BioSupraMol, Thielallee 63, D-14195 Berlin, Germany; [email protected] 
First page
3719
Publication year
2021
Publication date
2021
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2548693944
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.